Glottis IPO Day 3: Check Subscription Status & Key Highlights

01 October 2025
1 min read
whatsapp
facebook
copyToClipboard

The Glottis IPO enters its third day of subscription today, 1 October 2025. Till the end of Day 2, the issue was subscribed to 2.23 times. 

Glottis IPO: Issue Details

  • Issue Size: Glottis IPO is a book-building issue of ₹307 crore, comprising a fresh issue of 160 crore shares and an offer for sale (OFS) of ₹147 crore. 
  • Price Band: The price band is set between ₹120 and ₹129 per share.
  • Book-running lead manager: Smart Horizon Capital Advisors Private Limited
  • Registrar: Pantomath Capital Advisors Private Limited
  • Listing: The shares are proposed to be listed on the NSE and the BSE on October 7. 

Glottis IPO Day 3: Subscription Details

[1-October-2025 12:03:00]

Investor Category

Subscription (Times)

Qualified Institutional Buyers (QIBs)

1.79

Non-Institutional Investors

1.47

Retail Individual Investors (RIIs)

0.95

Total

1.26

Glottis IPO Day 2: Subscription Details

[30-September-2025 17:03:00]

Investor Category

Subscription (Times)

Qualified Institutional Buyers (QIBs)

1.79

Non-Institutional Investors

1.08

Retail Individual Investors (RIIs)

0.58

Total

0.93

Utilisation of IPO Proceeds

The company aims to use the net proceeds from the fresh issue towards the following objectives. 

  • Fund capital expenditure requirements towards the purchase of commercial vehicles and containers
  • General corporate purposes 

Glottis Business Overview 

Glottis provides comprehensive, multimodal logistics solutions across domestic and international markets. This includes ocean freight forwarding, air freight forwarding, and road transportation.  In addition to core transportation services, the company also provides a range of value-added logistics support, including warehousing, cargo storage, customs clearance, cargo handling, and third-party logistics (3PL) services.

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory. 

To read the RA disclaimer, please click here.

Do you like this edition?